Evidence map›Paper›PMID 29799976›Full record

ArticleJAMA oncology2018

Assessment of a Noninvasive Exhaled Breath Test for the Diagnosis of Oesophagogastric Cancer.

Sheraz R Markar, Tom Wiggins, Stefan Antonowicz, Sung-Tong Chin, Andrea Romano, Konstantin Nikolic, Benjamin Evans, David Cunningham, Muntzer Mughal, Jesper Lagergren and 1 more

2 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in JAMA oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 64 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 8 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05557955 completednot on this mapstarted 2022, after this paper: background citation

Predicting Clinical Outcomes Based on Dynamic Breathomics Testing in Esophageal Squamous Cell Carcinoma Receiving Chemoradiotherapy: A Prospective Observational Study (EC-CRT-005)

TypeobservationalSponsorMian XIRan2022 to 2023Enrolled210ConditionsEsophageal Squamous Cell CarcinomaArmsBreathing test
NCT05600608 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Augmentation of Volatile Biomarkers of Oesophageal and Gastric Adenocarcinoma From the Tumour Lipidome

TypeinterventionalSponsorAnuja MitraRan2022 to 2023Enrolled100ConditionsBreath Test, Oesophageal Cancer, Gastric Cancer, AugmentationArmsOral Stimulant Drink
3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 8 syntheses or guidelines pooled it, 126 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Breath biomarkers for esophageal cancer: identification, quantification, and diagnostic modeling.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025
    Article
  19. Article
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Sheraz R MarkarDepartment Surgery & Cancer, Imperial College London, United Kingdom.
Tom WigginsDepartment Surgery & Cancer, Imperial College London, United Kingdom.
Stefan AntonowiczDepartment Surgery & Cancer, Imperial College London, United Kingdom.
Sung-Tong ChinDepartment Surgery & Cancer, Imperial College London, United Kingdom.
Andrea RomanoDepartment Surgery & Cancer, Imperial College London, United Kingdom.
Konstantin NikolicInstitute of Biomedical Engineering, Imperial College London, United Kingdom.
Benjamin EvansInstitute of Biomedical Engineering, Imperial College London, United Kingdom.
David CunninghamDepartment of Oncology, Royal Marsden Hospital, London, United Kingdom.
Muntzer MughalDepartment of Surgery, University College London Hospital, United Kingdom.
Jesper LagergrenDepartment of Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
George B HannaDepartment Surgery & Cancer, Imperial College London, United Kingdom.
Imperial College London · GBKing's College London · GBNIHR Imperial Biomedical Research Centre · GBRoyal Marsden Hospital · GBUniversity College Hospital · GB

Funding

Department of Health DRF-2014-07-088
6 · The paper itself

Abstract

Importance: Early esophagogastric cancer (OGC) stage presents with nonspecific symptoms. Objective: The aim of this study was to determine the accuracy of a breath test for the diagnosis of OGC in a multicenter validation study. Design, Setting, and Participants: Patient recruitment for this diagnostic validation study was conducted at 3 London hospital sites, with breath samples returned to a central laboratory for selected ion flow tube mass spectrometry (SIFT-MS) analysis. Based on a 1:1 cancer:control ratio, and maintaining a sensitivity and specificity of 80%, the sample size required was 325 patients. All patients with cancer were on a curative treatment pathway, and patients were recruited consecutively. Among the 335 patients included; 172 were in the control group and 163 had OGC. Interventions: Breath samples were collected using secure 500-mL steel breath bags and analyzed by SIFT-MS. Quality assurance measures included sampling room air, training all researchers in breath sampling, regular instrument calibration, and unambiguous volatile organic compounds (VOCs) identification by gas chromatography mass spectrometry. Main Outcomes and Measures: The risk of cancer was identified based on a previously generated 5-VOCs model and compared with histopathology-proven diagnosis. Results: Patients in the OGC group were older (median [IQR] age 68 [60-75] vs 55 [41-69] years) and had a greater proportion of men (134 [82.2%]) vs women (81 [47.4%]) compared with the control group. Of the 163 patients with OGC, 123 (69%) had tumor stage T3/4, and 106 (65%) had nodal metastasis on clinical staging. The predictive probabilities generated by this 5-VOCs diagnostic model were used to generate a receiver operator characteristic curve, with good diagnostic accuracy, area under the curve of 0.85. This translated to a sensitivity of 80% and specificity of 81% for the diagnosis of OGC. Conclusions and Relevance: This study shows the potential of breath analysis in noninvasive diagnosis of OGC in the clinical setting. The next step is to establish the diagnostic accuracy of the test among the intended population in primary care where the test will be applied.

Indexed as

AdultAgedBreath TestsEsophageal NeoplasmsFemaleHumansMaleMiddle AgedStomach Neoplasms

Identifiers

PMID29799976
PMCPMC6145735
OpenAlexW2804686217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.